Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | JAK1 | P23458 | 4/20 | 0.38 |
| ▸ | TYK2 | P29597 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.38 |
| ▸ | TTK | P33981 | 4/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21252298 | 0.92 | TTK (0.38) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL21251781 | 0.90 | JAK2 (0.36) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL24488400 | 0.90 | MAP3K12 (0.38) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL24488267 | 0.88 | JAK2 (0.37) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL21252199 | 0.86 | TTK (0.39) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL30442688 | 0.86 | TTK (0.34) | TTK | |
| SCHEMBL21252019 | 0.85 | TTK (0.37) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL24488377 | 0.85 | NOS1 (0.44) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL21252282 | 0.84 | JAK2 (0.34) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL30443541 | 0.84 | TTK (0.34) | TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3524603-B1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2022-06-08 | — | — | EP | disclosed |
| EP-3524603-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |